Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 29;122(30):e2505152122.
doi: 10.1073/pnas.2505152122. Epub 2025 Jul 21.

A preclinical pig model of Angelman syndrome mirrors the early developmental trajectory of the human condition

Affiliations

A preclinical pig model of Angelman syndrome mirrors the early developmental trajectory of the human condition

Luke S Myers et al. Proc Natl Acad Sci U S A. .

Abstract

Angelman syndrome is a neurodevelopmental disorder characterized by severe motor and cognitive deficits. It is caused by the loss of the maternally inherited allele of the imprinted ubiquitin-protein ligase E3A (UBE3A) gene. Rodent models of Angelman syndrome do not fully recapitulate all the symptoms associated with the condition and are limited as a preclinical model for therapeutic development. Here, we show that pigs (Sus scrofa) with a maternally inherited deletion of UBE3A (UBE3A-/+) have altered postnatal behaviors, impaired vocalizations, reduced brain growth, motor incoordination, and ataxia. Neonatal UBE3A-/+ pigs exhibited several symptoms observed in infants with Angelman syndrome, including hypotonia, suckling deficits, and failure to thrive. Collectively, these findings are consistent with the pathophysiology and developmental trajectory observed in individuals with Angelman syndrome. We anticipate that this pig model will advance our understanding of the pathophysiology of Angelman syndrome and be used as a preclinical large animal model for therapeutic development.

Keywords: CRISPR/Cas9; Sus scrofa; UBE3A; angelman syndrome; pig.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement:S.V.D. is employed at Ultragenyx Pharmaceutical Inc., S.V.D. has equity in Ultragenyx Pharmaceutical Inc., S.V.D. has research support from Ultragenyx Pharmaceutical Inc.

References

    1. Thibert R. L., Larson A. M., Hsieh D. T., Raby A. R., Thiele E. A., Neurologic manifestations of Angelman syndrome. Pediatr. Neurol. 48, 271–279 (2013). - PubMed
    1. Mertz L. G., et al. , Angelman syndrome in Denmark. Birth incidence, genetic findings, and age at diagnosis. Am. J. Med. Genet. A. 161A, 2197–2203 (2013). - PubMed
    1. Williams C. A., et al. , Angelman syndrome 2005: Updated consensus for diagnostic criteria. Am. J. Med. Genet. A. 140, 413–418 (2006). - PubMed
    1. Clayton-Smith J., Laan L., Angelman syndrome: A review of the clinical and genetic aspects. J. Med. Genet. 40, 87–95 (2003). - PMC - PubMed
    1. Matsuura T., et al. , De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat. Genet. 15, 74–77 (1997). - PubMed

Substances

LinkOut - more resources